[O-06] 一般演題口演セッション06

[O-06-4] Rozanolixizumab in MuSK antibody-positive myasthenia gravis: Phase 3 outcomes [Encore Presentation]

槍澤 公明^1,15, Kaminski Henry^2,15, Druzdz Artur^3,15, Grosskreutz Julian^4,15, Habib Ali A^5,15, Mantegazza Renato^6,15, Sacconi Sabrina^7,15, 杉本 太路^8,15, 鈴木 重明^9,15, 髙橋 正紀^10,15, Vissing John^11,15, Vu Tuan^12,15, Boehnlein Marion¹³, Greve Bernhard¹³, Bril Vera^14,15 (1.総合花巻病院 脳神経内科, 2.Department of Neurology & Rehabilitation Medicine, George Washington University, 3.Department of Neurology, Municipal Hospital Poznan, 4.Precision Neurology, Department of Neurology, University of Lubeck, 5.Department of Neurology, University of California, 6.Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Neurologico Carlo Besta, 7.Universite Cote d’Azur, Peripheral Nervous System and Muscle Department, Pasteur 2 Hospital, Centre Hospitalier Universitaire de Nice, 8.広島市立広島市民病院 脳神経内科, 9.慶應義塾大学 医学部 神経内科, 10.大阪大学大学院医学系研究科 生体病態情報科学講座 臨床神経生理学, 11.Copenhagen Neuromuscular Center, Department of Neurology, Rigshospitalet, University of Copenhagen, 12.Department of Neurology, University of South Florida Morsani College of Medicine, 13.UCB Pharma, 14.University Health Network, 15.MycarinG Study investigators)